XML 60 R50.htm IDEA: XBRL DOCUMENT
v3.22.2

Collaborative and Licensing Agreements - Additional Information (Detail) - Endo Pharmaceuticals Inc [Member] $ in Millions | 6 Months Ended
--- | ---
Jun. 30, 2022 USD ($)
Royalty terms | first commercial sale of the product in that country and extends until the later of the expiration, unenforceability or invalidation of the last valid claim of any licensed patent or application covering the licensed product in the country or the expiration of 10 years after the first commercial sale of the licensed product in the country, which period is referred to as the royalty term. Upon the expiration of the royalty term for a product in a country
Completion Of Stage One [Member] |
Milestone payments to be paid | $ 0.3
Completion Of Stage Two [Member] |
Milestone payments to be paid | $ 0.8

X
- Definition Milestone payments to be paid. + References No definition available. + Details
Name: | trvi_MilestonePaymentsToBePaid
Namespace Prefix: | trvi_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Royalty terms. + References No definition available. + Details
Name: | trvi_RoyaltyTermsAndConditions
Namespace Prefix: | trvi_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | dei_LegalEntityAxis=trvi_EndoPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=trvi_CompletionOfStageOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=trvi_CompletionOfStageTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |